iBio logo
iBio
IBIO | NASDAQ
Chart Builder DCF Calculator
$0.71
-$0.02 (-2.97%)
At close: Nov 16, 2026, 4:00 PM ET
$0.69
-$0.02 (-2.11%)
After-hours: Nov 16, 2026, 7:55 PM ET

iBio Company Profile

Company profile explained

Company Profile

iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.

Key Executives

Name Position
Martin Brenner Chief Executive Officer, Chief Scientific Officer & Director
Marc Banjak Chief Legal Officer
Cory Schwartz Director of Research and Early Development
Felipe Duran CFO & Principal Accounting Officer
Molly Carr Chief Medical Officer

Latest SEC Filings

Date Type Title
Oct 19, 2026 8-K Current Report
Oct 15, 2026 4 Filing
Oct 15, 2026 4 Filing
Oct 15, 2026 4 Filing
Oct 15, 2026 4 Filing
Oct 15, 2026 4 Filing
Oct 15, 2026 4 Filing
Oct 14, 2026 SC 13G Statement of acquisition of beneficial ownership b...
Oct 13, 2026 8-K Current Report
Sep 14, 2026 8-K Current Report
View All SEC Filings ➞
iBio
iBio logo
Country United States
IPO Date Aug 19, 2008
Industry Biotechnology
Sector Healthcare
Employees 23
CEO Martin Brenner

Contact Details

11750 Sorrento Valley Road San Diego, California 92121 United States

Stock Details

Ticker Symbol IBIO
Exchange NASDAQ
Fiscal Year July - June
Reporting Currency USD
CIK Code 0001420720
CUSIP Number 451033708
ISIN Number US4510337086
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.